Skip to main content
Equibles

JANE STREET GROUP, LLC

Position in SABS — SAB Biotherapeutics, Inc.

CIK 1595888 NEW YORK, NY
Back to SABS Full portfolio

Position in SABS

as of Jun 30, 2026 · filed Aug 14, 2026
Position Value
$57,072
+$57,072 QoQ
Shares Held
14,634
Ownership
0.016%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2021
11 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in SABS Over Time

Shares Held

Position Value (USD)

Derivatives in SABS

reported options exposure · as of Jun 30, 2026
CallValue
$209,040
CallShares
53,600
PutValue
$883,350
PutShares
226,500

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Jun 30, 2026

JANE STREET GROUP, LLC holds $1,373,713,627 across 292 Biotechnology names. SABS ranks #236 (0.0% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 BBIO
BridgeBio Pharma, Inc.
 2,934,193 $218,538,693
2 MDGL
Madrigal Pharmaceuticals, Inc.
 191,541 $102,847,939
3 AXSM
Axsome Therapeutics, Inc.
 403,995 $98,885,855
4 TGTX
Tg Therapeutics, Inc.
 1,752,646 $96,290,370
5 EXEL
Exelixis, Inc.
 1,402,438 $76,306,651
6 QURE
uniQure N.V.
 1,610,483 $74,178,846
7 HALO
Halozyme Therapeutics, Inc.
 694,684 $54,372,915
8 TVTX
Travere Therapeutics, Inc.
 938,699 $53,327,489

All Filings in SABS

Export CSV
6 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $883,350 226,500
2026-06-30 $209,040 53,600
2026-06-30 $57,072 14,634
2026-03-31 $276,143 72,100
2026-03-31 $39,449 10,300
2022-09-30 $16,791 23,954